$46.53
-2.21-4.53%
Last update: Nov 10, 6:52 PM
Edgewise Therapeutics Inc
EWTXNASDAQ
Edgewise Therapeutics rose 166.6% from $18.28 to a 1-year high of $48.74, ahead of the S&P 500's +10.0%. Its worst day was Dec 22 (−18.0%), and its low came Nov 10 at $18.28.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Edgewise Therapeutics shares rose 17.5%, while the S&P 500 rose 0.2%.
+17.5% · S&P 500 +0.2%
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel oral, selective, cardiac sarcomere modulator, specifically designed
Story events cover the past 12 months · Times ET
+25.5%, the year's best day · S&P 500 +0.4%
Edgewise Therapeutics shares rose 12.9%, while the S&P 500 fell 0.5%.
+12.9% · S&P 500 −0.5%
EPS of $-0.47 missed the $-0.44 estimate on $0.00 revenue.
−1.5% · S&P 500 −0.6%
EPS of $-0.46 beat the $-0.49 estimate on $0.00 revenue.
−3.8% · S&P 500 −0.3%
The transaction meaningfully strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the Company’s strategic focus to accelerate and unlock the full potential of its
+17.9% · S&P 500 +0.3%
EPS of $-0.53 missed the $-0.48 estimate on $0.00 revenue.
−1.3% · S&P 500 −0.2%
EPS of $-0.19 missed the $1.90 estimate on $0.00 revenue (est. $119.2M).
−0.4% · S&P 500 +1.7%
Where it ended: a 1-year high close of $48.74 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.47, revenue est. $9.6M).
Nothing in the past 12 months.
All EWTX dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for EWTX and SPY from Benzinga historical bars. Not investment advice.
